This study is in progress, not accepting new patients
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at UCLA UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Dolores Shoback (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Dolores Shoback (ucsf)
Dr. Dolores Shoback cares for patients with a variety of disorders related to the endocrine system, focusing particularly on metabolic bone disease, parathyroid disorders and osteoporosis. She also directs UCSF's physician training program in diabetes, endocrinology and metabolism. Shoback's research interests include metabolic bone disease, the calcium-sensing receptor and parathyroid hormone.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc.
- ID
- NCT05778071
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 165 study participants
- Last Updated